These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 17549353)

  • 1. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
    Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
    Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.
    Matsuyama M; Yoshimura R; Mitsuhashi M; Hase T; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
    Int J Oncol; 2004 Apr; 24(4):821-7. PubMed ID: 15010818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cysteinylLT1 receptor in human renal cell carcinoma.
    Funao K; Matsuyama M; Naganuma T; Kawahito Y; Sano H; Nakatani T; Yoshimura R
    Mol Med Rep; 2008; 1(2):185-9. PubMed ID: 21479395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cysteinylLT1 receptor in human testicular cancer and growth reduction by its antagonist through apoptosis.
    Matsuyama M; Funao K; Kawahito Y; Sano H; Chargui J; Touraine JL; Nakatani T; Yoshimura R
    Mol Med Rep; 2009; 2(2):163-7. PubMed ID: 21475807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer.
    Segawa Y; Yoshimura R; Hase T; Nakatani T; Wada S; Kawahito Y; Kishimoto T; Sano H
    Prostate; 2002 May; 51(2):108-16. PubMed ID: 11948965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between cysteinyl-leukotriene-1 receptor and human transitional cell carcinoma in bladder.
    Matsuyama M; Funao K; Hayama T; Tanaka T; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
    Urology; 2009 Apr; 73(4):916-21. PubMed ID: 19167045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
    Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
    Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Das S; Roth CP; Wasson LM; Vishwanatha JK
    Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells.
    Paruchuri S; Mezhybovska M; Juhas M; Sjölander A
    Oncogene; 2006 Oct; 25(50):6660-5. PubMed ID: 16715140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
    Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
    Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation.
    Nieves D; Moreno JJ
    Biochem Pharmacol; 2006 Oct; 72(8):1022-30. PubMed ID: 16934759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
    Man YG; Gardner WA
    Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cyclooxygenase-2 in prostate carcinoma.
    Yoshimura R; Sano H; Masuda C; Kawamura M; Tsubouchi Y; Chargui J; Yoshimura N; Hla T; Wada S
    Cancer; 2000 Aug; 89(3):589-96. PubMed ID: 10931458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of cholesterol and phytosterols on cell proliferation, apoptosis and expression of a prostate specific gene in prostate cancer cell lines.
    Ifere GO; Barr E; Equan A; Gordon K; Singh UP; Chaudhary J; Igietseme JU; Ananaba GA
    Cancer Detect Prev; 2009; 32(4):319-28. PubMed ID: 19186008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist- and T(H)2 cytokine-induced up-regulation of cysteinyl leukotriene receptor messenger RNA in human monocytes.
    Shirasaki H; Seki N; Fujita M; Kikuchi M; Kanaizumi E; Watanabe K; Himi T
    Ann Allergy Asthma Immunol; 2007 Oct; 99(4):340-7. PubMed ID: 17941281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.
    Zhou T; Xu C; He M; Sun Y
    Prostate Cancer Prostatic Dis; 2008; 11(2):143-7. PubMed ID: 17637760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
    Dizeyi N; Bjartell A; Nilsson E; Hansson J; Gadaleanu V; Cross N; Abrahamsson PA
    Prostate; 2004 May; 59(3):328-36. PubMed ID: 15042609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
    Zovko A; Yektaei-Karin E; Salamon D; Nilsson A; Wallvik J; Stenke L
    Oncol Rep; 2018 Aug; 40(2):902-908. PubMed ID: 29845257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
    Zha S; Gage WR; Sauvageot J; Saria EA; Putzi MJ; Ewing CM; Faith DA; Nelson WG; De Marzo AM; Isaacs WB
    Cancer Res; 2001 Dec; 61(24):8617-23. PubMed ID: 11751373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.